Abstract: Novel compounds having potassium channel activating activity and useful, for example, as antiischemic agents are disclosed. These compounds have the general formula ##STR1## wherein A is ##STR2## or a single bond to complete an indoline nucleus; X is --O--, --S-- or --NCN; and the R groups are as defined herein.

Abstract: Compounds which are useful as inhibitors of cholesterol biosynthesis and thus as hypocholesterolemic agents are provided which have a quinoline or a pyridine anchor attached by means of a linker to a binding domain sidechain, which compounds inhibit the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase.

Abstract: A radiology kit for use with a catheter includes a first connection member 20 for attachment to the skin of the patient around the stomal orifice and a second connection member 30 (a cap) constructed for releasable attachment to a first connection means, i.e. a rib 23, on the first connection member. The cap has an end wall 33 with a hole 39 therein through which a catheter 40 can be threaded. A third connection member 50 of the kit is attached to a drainage sleeve 52 and constructed for releasable attachment to a second connection means, i.e. a rib 25 on the first connection member 20.

Abstract: A male incontinence device has one coupling part 200 attachable to a silicone pad 500 and a second coupling part 300 attached to a condom-like drainage member 400. A stretchable ring or wall 312 can be shifted ("snapped") by manual pressure between a locking position wherein the two coupling parts are locked together and an unlocking position wherein the two coupling parts can be separated to permit removal of the condom-like drainage member from the silicone pad.

Abstract: Diuresis, natriuresis, and the lowering of blood pressure are produced in a host by administering one or more neutral endopeptidase inhibitors. An additional blood pressure lowering agent such as an angiotensin converting enzyme inhibitor can be administered along with the neutral endopeptidase inhibitor.

Abstract: Compounds are disclosed having the formula ##STR1## These compounds inhibit the action of angiotensin II and are useful, therefore, for example, as antihypertensive agents.

Abstract: A process for preparing compounds of the formula ##STR1## where a, b, c, R.sub.1, R.sub.2, and R.sub.3 are as defined herein including the step of alkylating a phenol of formula ##STR2## with an acetylene of formula ##STR3## where X is chlorine; bromine; --OC(O)--R.sub.5, where R.sub.5 is alkyl, aryl or substituted aryl; or --OCO.sub.2 R.sub.6, where R.sub.6 is alkyl or ##STR4## in the presence of a catalytic amount of a cuprous or cupric salt. The compounds of formula I are intermediates useful in the preparation of pyranyl cyanoguanidine derivatives.

Abstract: A method is provided for treating hypertension in normotensive patients having insulin resistance by administering a cholesterol lowering drug, such as pravastatin, alone or in combination with an ACE inhibitor, especially one containing a mercapto moiety, such as captopril or zofenopril.

Abstract: A novel, overall process for the preparation of a compound of the formula I: ##STR1## where R.sup.1 and R.sup.2 are each independently hydrogen, an alkyl group, a cycloalkyl group, an aryl group or, taken together with the carbon atom to which they are attached, form a cycloalkyl group; andR.sup.3 is hydrogen, an alkyl group, or an aryl group, or salts thereof, useful as intermediates in the preparation of HMG-CoA reductase inhibitors; novel methods within the overall process; and novel intermediates produced by those methods.

Abstract: Novel compounds useful, for example, for the treatment of ischemic conditions and arrhythmia are disclosed. The compounds have the formula ##STR1## wherein X is oxygen or sulfur and the R groups are as defined herein.

Abstract: A method is provided for treatment of neuronal insult, such as caused by lack of oxygen, which neurons are prone to Parkinsonian degeneration by administering an ATP-sensitive potassium channel blocker, such as a sulfonyl urea, for example, tolbutamide.

Abstract: The wound dressing securement device has one or more flexible adhesive base member strips that are secured to the skin around or at opposite sides of a wound with sufficient clearance for a wound dressing. A plurality of sheet retention members joined to one or more of the base members project vertically from an exposed surface of the base member. A flexible, foldable, stretchable hold-down sheet member has a plurality of openings to engage with engagement heads provided on the sheet retention members. The hold-down sheet member is sized to form a cover for the underlying wound dressing and bears against the wound dressing to hold it in position on the wound. When the wound dressing is to be changed, the hold-down sheet member is disengaged from the sheet retention members to uncover the wound dressing, and make it accessible for removal and replacement. The adhesive base member(s) remain in place during repeated changes of the wound dressing.

Abstract: Hypotensive activity is exhibited by new phosphonate substituted amino or imino acids of the formula ##STR1## isomeric mixtures thereof and pharmaceutically acceptable salts thereof, wherein:X is an imino or amino acid of the formula ##STR2##

Abstract: A method is provided for inhibiting cholesterol biosynthesis by inhibiting de novo squalene production employing methylene phosphonoalkylphosphinate compounds.

Abstract: S-enantiomers of the formula ##STR1## result from the reaction of a racemic form of compound I with an alcohol in the presence of an enzyme capable of selectively esterifying the R-enantiomers of the racemic compound.

Abstract: An enzymatic reduction method, particularly a stereoselective enzymatic reduction method, for the preparation of compounds useful as intermediates in the preparation of taxanes.

Abstract: Antibacterial activity is exhibited by novel compounds having the formula ##STR1## where R.sub.1, R.sub.2, and M are as defined herein and X is --(CH.sub.2).sub.n -- wherein n is 0, 1, 2, 3 or 4 or CR.sub.3 R.sub.4 wherein R.sub.3 and R.sub.4 are the same or different and each is hydrogen, --CH.sub.3 or --C.sub.2 H.sub.5 or R.sub.3 and R.sub.4 taken together with the carbon atom to which they are attached form a 3, 4, 5, 6 or 7-membered cycloalkyl ring. Also described are various intermediates for the preparation of compounds of formula 1.

Abstract: The separation device includes a container having a dome-shaped base and a peripheral wall surrounding the base to define a chamber for receiving a random mixture of defective and nondefective articles. A spiral-shaped ramp on the peripheral wall which surrounds the chamber and overhangs the base, leads to an elevated outlet opening. A vibrating device vibrates the chamber to excite movement of the defective and nondefective articles along the base and onto and up the ramp toward the outlet opening. The container also includes trap openings in the base and ramp to eliminate defective articles from the chamber. Discriminating devices are provided on the ramp that cause defective material to fall from the ramp back onto the base of the chamber. Only the nondefective articles can move on the ramp past the trapping devices toward the outlet of the container for transfer to another processing station.

Abstract: Compounds of the formula ##STR1## wherein Z is ##STR2## proline, pipecolic acid, an indolecarboxylic acid or an isoquinolinecarboxylic acid. These compounds are useful as cardiovascular agents.

Abstract: An enantiomerically pure compound of the formula ##STR1## is prepared when the associated racemic mixture is reacted with an acrylating agent R.sup.3 --C(O)--O--R in the presence of a microorganism or enzyme derived therefrom capable of catalyzing transesterification of an alcohol. X.sup.1 and X.sup.2 are each independently halogen, R is alkyl, R.sup.1 and R.sup.2 are each independently alkyl, cycloalkyl, aralkyl or aryl and R.sup.3 is alkyl, cycloalkyl, aryl or aralkyl.